1. [Current developments and perspectives in targeted therapies]
- Author
-
Nicolas, Dickgreber, Rudolf M, Huber, Martin, Reck, Niels, Reinmuth, Wolfgang, Schütte, Monika, Serke, and Jürgen, Wolf
- Subjects
Genetic Markers ,Lung Neoplasms ,Oncogene Proteins, Fusion ,DNA Mutational Analysis ,Aftercare ,Receptor Protein-Tyrosine Kinases ,Antineoplastic Agents ,Receptors, Somatomedin ,Drugs, Investigational ,Protein-Tyrosine Kinases ,Prognosis ,ErbB Receptors ,Gene Expression Regulation, Neoplastic ,Drug Delivery Systems ,Receptors, Vascular Endothelial Growth Factor ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Anaplastic Lymphoma Kinase ,Neoplasm Staging - Abstract
Many different approaches for improving the prognosis of patients with advanced non-small-cell lung cancer (NSCLC) are currently being investigated. This article discusses the significance of maintenance therapy after primary chemotherapy and reviews study data on second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), inhibitors of insulin-like growth factor receptors (IGFR), vascular-disrupting agents (VDAs) and multi-TKIs of vascular endothelial growth factor receptors (VEGFR). The article also looks at the future prospects of using genetic markers in the field of NSCLC.
- Published
- 2010